HUMAN KUNITZ KALLIKREIN INHIBITOR THERAPY FOR ARTHRITIS

描述（改编自应用程序）：该应用程序的单一具体目标 第一阶段的建议是测试假设，有效的激肽释放酶抑制剂， EPI-K503可以预防和/或治疗PG-APS诱导的炎性关节炎及其 相关的全身性炎症。提出这一建议的理由是， 特异性抑制激肽释放酶将阻止其作用恶化 炎性变化。计划中的抑制剂是一种类似于抑肽酶的肽 将其注射到已建立的急性和慢性 复发性炎性侵蚀性关节炎，并进行适当的控制。 关节的炎症变化和炎症的全身性测量将是 评估。如果抑制剂成功地减少了关节炎， 系统性炎症，有计划进行II期研究， 具有相关结构的酶的非肽抑制剂，并测试这些 在炎症性肠病的模型中。 拟定商业应用：不可用

DESCRIPTION (Adapted from the application): The single specific aim of this Phase I proposal is to test the hypothesis that the potent kallikrein inhibitor EPI-K503 can prevent and/or treat PG-APS-induced inflammatory arthritis and its associated systemic inflammation. The rationale for this proposal is that specific inhibition of the enzyme kallikrein will block its effects to worsen inflammatory changes. The planned inhibitor is a peptide analogous to aprotinin that will be injected into an established rat model of acute and chronic relapsing inflammatory erosive arthritis, with appropriate controls. Inflammatory changes in joints and systemic measures of inflammation will be assessed. If the inhibitor is successful in decreasing the arthritis and systemic inflammation, there are plans for a Phase II study to develop non-peptide inhibitors of the enzyme with related structures, and to test these in a model of inflammatory bowel disease. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE